Teva Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its supplemental new drug application (sNDA) for three-times-a-week COPAXONE 40mg/mL, a new dose of COPAXONE. COPAXONE (glatiramer acetate ...
The USFDA has accepted Teva Pharmaceutical Industries' supplemental new drug application (sNDA) for reviewing Copaxone (glatiramer acetate injection) 40mg/1mL. Indicated for patients with relapsing-remitting multiple sclerosis (RRMS), the ...
Tags: Drug Application, Medicine
Teva Pharmaceutical Industries has reported that the Glatiramer Acetate Low-Frequency Administration (GALA) study evaluating a new dose of glatiramer acetate injection (GA) met its primary endpoint. The Phase III trial evaluated the ...
Tags: Teva Pharmaceutical Industries, Medicine, glatiramer acetate injection